Share on LinkedInShare on LinkedIn

ARTICLE · 25 FEBRUARY 2011

Celgene Corp. v. Canada (Attorney General)

In this case, the Supreme Court of Canada upheld a regulatory board’s decision to interpret its statutory mandate with reliance on a consumer protection purpose.

CanadaIntellectual Property

2011 SCC 1 (Released 20 January 2011)

Statutory Interpretation – Patented Medicine Prices Review Board – Consideration of Mandate – Standard of Review

In this case, the Supreme Court of Canada upheld a regulatory board's decision to interpret its statutory mandate with reliance on a consumer protection purpose.

The issue before the Patented Medicine Prices Review Board ("Board") was the extent of the Board's jurisdiction over medicine "sold in any market in Canada". The Board is constituted under the Patent Act. This Act permits the Board to investigate the price of a medicine, or to require the patentee of that medicine to provide the Board with information on that medicine's price, where the medicine "is being or has been sold in any market in Canada".

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from